Key clinical point: An armored chimeric antigen receptor (CAR) T-cell therapy has demonstrated efficacy in vitro and in patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Major finding: ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, proved more cytotoxic than traditional CAR T-cell therapy in vitro and produced responses in 12 of 13 NHL patients who received it.
Study details: Preclinical experiments and a phase 1 trial of 13 NHL patients. Eleven patients had diffuse large B-cell lymphoma (DLBCL), and two patients had follicular lymphoma.
Disclosures: Dr. Lu is employed by Innovative Cellular Therapeutics, which funded the research and is developing ICTCAR014.
Lu V et al. SITC 2019, Abstract O25.